Brian Piekos - 16 Jan 2026 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Financial Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
16 Jan 2026
Net transactions value
$0
Form type
4
Filing time
21 Jan 2026, 16:10:39 UTC
Previous filing
26 Nov 2025
Next filing
24 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Piekos Brian Chief Financial Officer C/O KALVISTA PHARMACEUTICALS, INC., 200 CROSSING BOULEVARD, FRAMINGHAM /s/ Benjamin L. Palleiko, Attorney-in-Fact 21 Jan 2026 0001815308

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Award $0 +100,000 $0.000000 100,000 16 Jan 2026 Common Stock 100,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate.